AstraZeneca: Lynparza delays pancreatic cancer progression
(CercleFinance.com) - AstraZeneca's Lynparza significantly delays disease progression in patients with metastatic pancreatic cancer, the company said on Tuesday.
Results from a Phase III trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Lynparza vs. placebo.
The trial - which randomised 154 patients with gBRCAm metastatic pancreatic cancer, whose disease had not progressed on 1st-line platinum-based chemotherapy - hence met its primary endpoint.
Pancreatic cancer is the 12th most common cancer worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Results from a Phase III trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Lynparza vs. placebo.
The trial - which randomised 154 patients with gBRCAm metastatic pancreatic cancer, whose disease had not progressed on 1st-line platinum-based chemotherapy - hence met its primary endpoint.
Pancreatic cancer is the 12th most common cancer worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.